{"organizations": [], "uuid": "17aed8ba6970ef4f6ed271b9d8562a769998178f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-motif-bio-initiates-nda-rolling-su/brief-motif-bio-initiates-nda-rolling-submission-for-iclaprim-and-provides-business-update-idUSASC09UM6", "country": "US", "domain_rank": 408, "title": "BRIEF-Motif Bio Initiates NDA Rolling Submission For Iclaprim And Provides Business Update", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-03T15:26:00.000+03:00", "replies_count": 0, "uuid": "17aed8ba6970ef4f6ed271b9d8562a769998178f"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-motif-bio-initiates-nda-rolling-su/brief-motif-bio-initiates-nda-rolling-submission-for-iclaprim-and-provides-business-update-idUSASC09UM6", "ord_in_thread": 0, "title": "BRIEF-Motif Bio Initiates NDA Rolling Submission For Iclaprim And Provides Business Update", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "nda", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 3, 2018 / 7:26 AM / Updated an hour ago BRIEF-Motif Bio Initiates NDA Rolling Submission For Iclaprim And Provides Business Update Reuters Staff \nApril 3 (Reuters) - Motif Bio PLC: \n* MOTIF BIO INITIATES NDA ROLLING SUBMISSION FOR ICLAPRIM AND PROVIDES BUSINESS UPDATE \n* INITIATION OF A ROLLING SUBMISSION OF A NEW DRUG APPLICATION (NDA) TO U.S. FOOD & DRUG ADMINISTRATION (FDA) FOR ICLAPRIM \n* NDA SUBMISSION IS EXPECTED TO BE COMPLETED DURING Q2 OF 2018. Source text for Eikon: Further company coverage:", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-03T15:26:00.000+03:00", "crawled": "2018-04-03T11:35:12.001+03:00", "highlightTitle": ""}